The Conversation (0)
UK Biobank Pharma Proteomics Project aims to create a comprehensive map of disease-associated protein levels in the human body to advance biomarker discovery
TruScreen Group Limited (NZX/ASX:TRU) is pleased to announce the preliminary publication, on 25 July 2024, of a study titled “Beyond Tradition: Investigating TruScreen’s Performance Versus Pap Smear in Cervical Cancer Detection” on Research Square1Link. The preliminary publication is subject to peer review.
Highlights
- 507 women tested from 2021-2022, results published in July 2024
- High Sensitivity and Specificity: TruScreen demonstrated a sensitivity of 83.3% and a specificity of 95% for detecting cervical lesions (neoplasms), compared to 66.7% and 98.2% for Pap smear, respectively1.
- Real-Time Results: The TruScreen device provides immediate screening results, eliminating the need for laboratory equipment and pathology staff.
- Practical and Reliable: The study confirmed that TruScreen is a practical and reliable screening tool, suitable for use in various healthcare settings.
The authors concluded that TruScreen “represents a reliable, practical screening tool for cervical neoplasms” and that their results “provide an evidence-based approach for policymakers when selecting the optimal cervical cancer screening strategy in countries without an established national screening program.”
This study reinforces TruScreen’s commitment to providing innovative and accessible healthcare solutions. The positive results validate TruScreen’s technology and opens new opportunities in the global healthcare market.
For more information, please visit our website at www.truscreen.com.
Click here for the full ASX Release
This article includes content from Truscreen, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
Thermo Fisher Scientific's Olink Platform Selected for World's Largest Human Proteome Study
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the UK Biobank Pharma Proteomics Project (UKB-PPP) has selected its Olink ® Explore Platform to support the world's largest human proteomics study of its kind. UKB-PPP aims to analyze more than 5,400 proteins from 600,000 samples to fuel the discovery of new protein biomarkers that can be used to predict, diagnose and treat diseases.
"Studies on the human proteome are having a profound impact on our customers' fundamental understanding of disease and the advancement of life sciences research," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher. "The unprecedented scale of this project, with support from our next-generation proteomics solution, underscores the potential to deepen their knowledge and develop new applications to improve human health."
Advancement of the Olink Explore Platform, which is designed to enable deep analysis of the thousands of proteins in the human body, provides researchers with the ability to study the role they play in many types of diseases. Published studies in this emerging field, known as population proteomics, have demonstrated the potential protein signatures have to help advance the future of precision medicine.
"Proteomics provides an incredibly detailed snapshot of health. This new frontier of science can unveil how genetics and external factors – like diet, exercise and climate – interact, and will help to pinpoint the key causes of diseases and identify drug targets," said Professor Naomi Allen, chief scientist of UK Biobank. "It has already led to important scientific discoveries, such as identifying proteins that can help to diagnose disease – including multiple sclerosis - and helping to identify those at higher risk of developing dementia and cancer many years before clinical diagnosis. Over 19,000 researchers around the world are using UK Biobank data; adding proteomic data to everything else we hold will enable scientists to make rapid discoveries to help diagnose and treat life-altering diseases."
UKB-PPP is a collaboration between UK Biobank and 14 leading biopharmaceutical companies, with the goal to make available important information on the human proteome to UK Biobank-approved researchers across the world. In turn, the data can be used to validate and identify new drug targets, advance diagnostics, and help accelerate targeted drug discovery to support the development of more effective and safer medications.
"UKB-PPP brings together scientists from the world's leading pharmaceutical companies with the most advanced research technologies," said Chris Whelan, Ph.D., chair and principal investigator of UKB-PPP. "Success for projects of this size depends on having partners with the ability to scale reliably and effectively. We are excited to once again have Thermo Fisher's Olink platform as the supporting proteomics technology to drive this study."
UKB-PPP builds on the findings released in 2023 from the pilot project, which also leveraged the Olink Explore platform to analyze more than 54,000 samples from UK Biobank . The research was first published in Nature in October 2023 and has already been cited more than 400 times, laying the foundation for scientists to better understand how and why diseases develop and to advance targeted treatments. One study, published in Nature Communications , leveraged data from the pilot study to identify protein risk factors for certain cancers up to seven years in advance of diagnosis.
UKB-PPP is scheduled to begin in Q1 2025, with plans to make the proteomic data available to UK Biobank-approved researchers in staggered releases starting in 2026, followed by the full dataset in 2027. UKB-PPP will initially analyze more than 5,400 proteins from 300,000 samples and seek supplemental funding to analyze an additional 300,000 samples, bringing the total for the project to 600,000 samples.
Acquired by Thermo Fisher in July 2024, the Olink proteomics platform is a next generation proteomics solution that empowers researchers to measure more than 5,400 proteins with high specificity, speed, and the flexibility to study complex biological processes.
To learn more about the Olink Platform, please visit www.thermofisher.com/olink
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20250109316914/en/
Media Contact Information:
Sandy Pound
Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com
Website: www.thermofisher.com
Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com
News Provided by Business Wire via QuoteMedia
Thermo Fisher Scientific's Olink Platform Selected for World's Largest Human Proteome Study
UK Biobank Pharma Proteomics Project aims to create a comprehensive map of disease-associated protein levels in the human body to advance biomarker discovery
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the UK Biobank Pharma Proteomics Project (UKB-PPP) has selected its Olink ® Explore Platform to support the world's largest human proteomics study of its kind. UKB-PPP aims to analyze more than 5,400 proteins from 600,000 samples to fuel the discovery of new protein biomarkers that can be used to predict, diagnose and treat diseases.
"Studies on the human proteome are having a profound impact on our customers' fundamental understanding of disease and the advancement of life sciences research," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher. "The unprecedented scale of this project, with support from our next-generation proteomics solution, underscores the potential to deepen their knowledge and develop new applications to improve human health."
Advancement of the Olink Explore Platform, which is designed to enable deep analysis of the thousands of proteins in the human body, provides researchers with the ability to study the role they play in many types of diseases. Published studies in this emerging field, known as population proteomics, have demonstrated the potential protein signatures have to help advance the future of precision medicine.
"Proteomics provides an incredibly detailed snapshot of health. This new frontier of science can unveil how genetics and external factors – like diet, exercise and climate – interact, and will help to pinpoint the key causes of diseases and identify drug targets," said Professor Naomi Allen, chief scientist of UK Biobank. "It has already led to important scientific discoveries, such as identifying proteins that can help to diagnose disease – including multiple sclerosis - and helping to identify those at higher risk of developing dementia and cancer many years before clinical diagnosis. Over 19,000 researchers around the world are using UK Biobank data; adding proteomic data to everything else we hold will enable scientists to make rapid discoveries to help diagnose and treat life-altering diseases."
UKB-PPP is a collaboration between UK Biobank and 14 leading biopharmaceutical companies, with the goal to make available important information on the human proteome to UK Biobank-approved researchers across the world. In turn, the data can be used to validate and identify new drug targets, advance diagnostics, and help accelerate targeted drug discovery to support the development of more effective and safer medications.
"UKB-PPP brings together scientists from the world's leading pharmaceutical companies with the most advanced research technologies," said Chris Whelan, Ph.D., chair and principal investigator of UKB-PPP. "Success for projects of this size depends on having partners with the ability to scale reliably and effectively. We are excited to once again have Thermo Fisher's Olink platform as the supporting proteomics technology to drive this study."
UKB-PPP builds on the findings released in 2023 from the pilot project, which also leveraged the Olink Explore platform to analyze more than 54,000 samples from UK Biobank . The research was first published in Nature in October 2023 and has already been cited more than 400 times, laying the foundation for scientists to better understand how and why diseases develop and to advance targeted treatments. One study, published in Nature Communications , leveraged data from the pilot study to identify protein risk factors for certain cancers up to seven years in advance of diagnosis.
UKB-PPP is scheduled to begin in Q1 2025, with plans to make the proteomic data available to UK Biobank-approved researchers in staggered releases starting in 2026, followed by the full dataset in 2027. UKB-PPP will initially analyze more than 5,400 proteins from 300,000 samples and seek supplemental funding to analyze an additional 300,000 samples, bringing the total for the project to 600,000 samples.
Acquired by Thermo Fisher in July 2024, the Olink proteomics platform is a next generation proteomics solution that empowers researchers to measure more than 5,400 proteins with high specificity, speed, and the flexibility to study complex biological processes.
To learn more about the Olink Platform, please visit www.thermofisher.com/olink
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20250109316914/en/
Media Contact Information:
Sandy Pound
Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com
Website: www.thermofisher.com
Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com
News Provided by Business Wire via QuoteMedia
Thermo Fisher Scientific to Present at 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 11:15 a.m. (EST).
You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com .
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20250103010446/en/
Media Contact Information:
Sandy Pound
Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com
Website: www.thermofisher.com
Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com
News Provided by Business Wire via QuoteMedia
Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, January 30, 2025
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full year 2024 before the market opens on Thursday, January 30, 2025, and will hold a conference call on the same day at 8:30 a.m. EST.
During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The access code is 706921. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com . The earnings press release and related information can also be found in that section of our website under the heading "Financials". A replay of the call will be available under "News, Events & Presentations" through Friday, February 14, 2025.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20250102048471/en/
Media Contact Information:
Sandy Pound
Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com
Website: www.thermofisher.com
Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com
News Provided by Business Wire via QuoteMedia
Zero Candida Technologies:Pioneering Technology-driven, Innovative Solution for Non-drug Treatment of Candidiasis
Founded by a team of seasoned entrepreneurs and healthcare experts, Zero Candida (TSXV:ZCT) is a fem-tech pioneer, combining advanced artificial intelligence with non-drug diagnostics and personalized treatment modalities in a single device. The company developed an innovative, first-of-its-kind solution to the diagnosis and treatment of Candidiasis, a fungal infection causing irritation, discharge and intense itchiness of the vagina and the vulva. The device offers precision therapy by eliminating fungal infections with over 99.99 percent effectiveness in just three hours, a revolutionary improvement over existing treatments.
Zero Candida is on track to complete clinical trials and file for FDA approval in 2024 with its innovative technology.
Zero Candida's SMART vaginal diagnostic device utilizes blue light therapy to treat this widespread condition without drugs. This non-drug therapy addresses key issues associated with conventional antifungal medications, including reduced risk of drug resistance, minimized side effects, and potential for faster symptom relief
Company Highlights
- Zero Candida Technologies is a fem-tech company focused on developing a SMART diagnostic and therapeutic device aimed at eliminating vaginal candidiasis (commonly known as yeast infection), a condition that affects three out four women globally.
- Candidiasis a fungal infection causing irritation, discharge and intense itchiness of the vagina and the vulva. In several cases, the current treatment for Candidiasis has been ineffective.
- Zero Candida has completed proof-of-concept studies, and demonstrated near-complete fungal eradication with over 99.99 percent effectiveness in just three hours.
- Founded by a team of experienced entrepreneurs and healthcare experts, the company is addressing the significant unmet needs of the women’s health market.
- The fem-tech segment of the med tech market is expected to grow at a CAGR of 18.2 percent and is estimated to reach nearly US$30 billion by 2032. North America dominated the global fem-tech market with a share of 52.91 percent in 2023.
- The company has already patented this technology in South Africa, while additional filings for patent application in the US and EU are underway.
This Zero Candida profile is part of a paid investor education campaign.*
Click here to connect with Zero Candida (TSXV:CZT) to receive an Investor Presentation